Title
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study
UMMS Affiliation
MassBiologics; Department of Medicine; Department of Biochemistry and Molecular Pharmacology
Publication Date
2013-04-01
Document Type
Article
Subjects
Liver Transplantation; Hepacivirus; Hepatitis C Antibodies
Disciplines
Biochemistry, Biophysics, and Structural Biology | Hepatology | Immunology and Infectious Disease | Therapeutics | Virus Diseases
Abstract
Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon-alpha and ribavirin therapy after LT has significant toxicity and limited efficacy. The effect of a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) on viral clearance was examined in a randomized, double-blind, placebo-controlled pilot study in patients infected with HCV genotype 1a undergoing LT. Subjects received 11 infusions of 50 mg/kg MBL-HCV1 (n=6) or placebo (n=5) intravenously with three infusions on day of transplant, a single infusion on days 1 through 7 and one infusion on day 14 after LT. MBL-HCV1 was well-tolerated and reduced viral load for a period ranging from 7 to 28 days. Median change in viral load (log10 IU/mL) from baseline was significantly greater (p=0.02) for the antibody-treated group (range -3.07 to -3.34) compared to placebo group (range -0.331 to -1.01) on days 3 through 6 posttransplant. MBL-HCV1 treatment significantly delayed median time to viral rebound compared to placebo treatment (18.7 days vs. 2.4 days, p
DOI of Published Version
10.1111/ajt.12083
Source
Am J Transplant. 2013 Apr;13(4):1047-54. doi: 10.1111/ajt.12083. Link to article on publisher's site
Journal/Book/Conference Title
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Related Resources
PubMed ID
23356386
Repository Citation
Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav BA, Leney M, Smith HL, Molrine DC. (2013). Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Biochemistry and Molecular Pharmacology Publications. https://doi.org/10.1111/ajt.12083. Retrieved from https://escholarship.umassmed.edu/bmp_pp/158